In order to actively respond to the requirements of upgrading national drug standards and deepen the construction of quality management system, our company has4the moon29The daily production, quality inspection, and research and development personnel carried out2025Special concentrated learning and training on the edition of the Chinese Pharmacopoeia. The purpose of this training is to comprehensively interpret the core revision content of the new pharmacopoeia, understand and apply the new standards, and ensure that enterprise production and quality control provide solid guarantees for drug safety and effectiveness.
?Our aluminum-plastic and butyl rubber productsZhao Xiu, the head of the Quality Department, introduces2025The Chinese Pharmacopoeia has strengthened the microbiological control, testing methods, and safety requirements for our products, with a focus on: (1) adding spectral analysis; (2) introducing new drafts such as sterility testing and endotoxin testing, and encouraging the use of rapid microbial detection technology to replace traditional time-consuming methods; （3） Revise packaging material standards, eliminate unreasonable testing items (such as odor detection), and emphasize standardized services in the research and development and production processes for discussion;
The company will take this training as an opportunity to further strengthen the following work: ?
（1） At this stage, through close communication with clients, tracking the supplementary content of the National Medical Products Administration and the Pharmacopoeia Commission, and updating the knowledge system in a timely manner;
（2） Strengthen the linkage between research and development, production, and quality inspection departments, and embed pharmacopoeia standards in advance in areas such as standardization and process changes. ?
2025The implementation of the Chinese Pharmacopoeia marks a new stage in the quality control of drugs in China. Our company will practice the concept of "quality first" with higher standards, provide safe and effective drugs for patients through continuous learning and technological innovation, and help promote the high-quality development of the industry.